University of California - San Francisco, United States.
University of California - San Francisco, United States.
Soc Sci Med. 2017 Aug;186:87-95. doi: 10.1016/j.socscimed.2017.05.043. Epub 2017 May 23.
There is growing concern among US-based clinicians, patients, policy makers, and in the media about the personal and community health risks associated with opioids. Perceptions about the efficacy and appropriateness of opioids for the management of chronic non-cancer pain (CNCP) have dramatically transformed in recent decades. Yet, there is very little social scientific research identifying the factors that have informed this transformation from the perspectives of prescribing clinicians. As part of an on-going ethnographic study of CNCP management among clinicians and their patients with co-occurring substance use, we interviewed 23 primary care clinicians who practice in safety-net clinical settings. In this paper, we describe the clinical and social influences informing three historic periods: (1) the escalation of opioid prescriptions for CNCP; (2) an interim period in which the efficacy of and risks associated with opioids were re-assessed; and (3) the current period of "opioid pharmacovigilance," characterized by the increased surveillance of opioid prescriptions. Clinicians reported that interpretations of the evidence-base in favor of and opposing opioid prescribing for CNCP evolved within a larger clinical-social context. Historically, pharmaceutical marketing efforts and clinicians' concerns about racialized healthcare disparities in pain treatment influenced opioid prescription decision-making. Clinicians emphasized how patients' medical complexity (e.g. multiple chronic health conditions) and structural vulnerability (e.g. poverty, community violence) impacted access to opioids within resource-limited healthcare settings. This clinical-social history of opioid prescribing practices helps to elucidate the ongoing challenges of CNCP treatment in the US healthcare safety net and lends needed specificity to the broader, nationwide conversation about opioids.
美国的临床医生、患者、政策制定者和媒体越来越关注与阿片类药物相关的个人和社区健康风险。在过去几十年中,人们对阿片类药物治疗慢性非癌性疼痛(CNCP)的疗效和适宜性的看法发生了巨大变化。然而,几乎没有社会科学研究从处方医生的角度确定促成这种转变的因素。作为对临床医生及其同时患有物质使用障碍的 CNCP 患者进行 CNCP 管理的一项正在进行的民族志研究的一部分,我们采访了 23 名在安全网临床环境中执业的初级保健临床医生。在本文中,我们描述了影响三个历史时期的临床和社会影响:(1)CNCP 阿片类药物处方的增加;(2)重新评估阿片类药物的疗效和相关风险的中间时期;(3)“阿片类药物药物警戒”的当前时期,其特点是增加了对阿片类药物处方的监测。临床医生报告说,支持和反对 CNCP 阿片类药物处方的证据基础的解释在更大的临床社会背景下演变。从历史上看,制药营销工作和临床医生对疼痛治疗中种族化医疗保健差异的关注影响了阿片类药物处方决策。临床医生强调了患者的医疗复杂性(例如多种慢性健康状况)和结构脆弱性(例如贫困、社区暴力)如何影响资源有限的医疗保健环境中获得阿片类药物的机会。这种阿片类药物处方实践的临床社会历史有助于阐明美国医疗保健安全网中 CNCP 治疗的持续挑战,并为更广泛的全国范围内关于阿片类药物的对话提供必要的具体内容。